Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry)

• DOI: 10.1093/europace/euaf054
• Publication Date: 2025-03-18T19:28:43Z
• Authors: Jan-Hendrik van d...; Felix Hohendanner; Emanuel Heil; Karolin Albert; David Duncker; Heidi Estner; Thomas Deneke; Abdul Parwani; Evgenij Potapov; Katharina Seuthe; Jonas Wörmann; Arian Sultan; Jan-Hendrik Schipper; Lars Eckardt; Florian Doldi; Patrick Lugenbiel; Helge Servatius; Gregor Thalmann; Tobias Reichlin; Moneeb Khalaph; Denise Guckel; Philipp Sommer; Daniel Steven; Jakob Lüker
• Keywords: Ischemic Cardiomyopathy

Abstract Background and Aims Patients with left-ventricular-assist-devices (LVAD) are at high risk for ventricular tachycardia (VT), data on VT ablation in LVAD patients is scarce. This multicentre registry assessed the mechanism of VT, procedural parameters, outcome (NCT06063811). Methods Data referred 9 tertiary care centres were collected retrospectively. Parameters included mechanisms, data, recurrence, mortality. Results Overall, 69 (90% male, mean age 60.7±8.4 years) undergoing 72 procedures included. Most conducted after intensification antiarrhythmic drug (AAD) treatment (18/72; 25%) or a prior combination ≥ 2 AADs (31/72; 43%). Endocardial low voltage areas detected all patients. The predominant was scar-related re-entry (76/96 VTs; 79%) 19/96 VTs (20%) related to cannula. Non-inducibility any achieved 28/72 (39%). No complication observed. extent endocardial scar associated recurrence. median follow-up 283 days (IQR 70-587 days). A total 3/69 lost follow-up, 10/69 (14%) transplanted, 26/69 (38%) died, 16/69 (23%) free from VT. Conclusion Although often last resort, feasible safe when performed experienced centres. These suffer burden, cardiomyopathy-associated rather than cannula-related seems be dominant substrate. recurrence despite extensive treatment, overall prognosis limited.